Digital Architect

Alcon rolls out UNITY CS platform in Canada. UNITY CS is designed to support greater surgical efficiency and consistency. August 27, 2026 Managing Editor, Rodman Media Alcon has launched the UNITY Cataract System (CS), its next-generation standalone cataract surgical platform, in the Great White North. The Canadian availability of UNITY CS builds on growing global momentum for the UNITY platform, which has already supported more than 285,000 procedures globally across 1,350 systems worldwide, according to the company. UNITY CS is Alcon's standalone cataract surgical system and part of the platform, which also includes UNITY Vitreoretinal Cataract System (VCS). While UNITY VCS supports both vitreoretinal and cataract procedures within one integrated platform, UNITY CS is dedicated specifically to cataract surgery. This launch is part of a broader wave of innovation from Alcon this year, with multiple new product introductions across surgical and therapeutic categories - including UNITY VCS, PanOptix Pro, and the Valeda photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD) - reflecting the company's mission to advance eye care through an expanding innovation pipeline. "[This]marks an exciting milestone for Alcon as we continue advancing the next generation of surgical innovation in Canada," said Mark Newson, country manager and head of Surgical, Alcon Canada. "With UNITY CS, we are bringing forward technology designed to help surgeons and surgical teams operate with greater efficiency, consistency, and confidence in cataract surgery while supporting a smoother workflow in the operating room." Designed to support greater surgical efficiency and consistency, UNITY CS leverages a novel phacoemulsification modality engineered to deliver up to two times faster nucleus removal^ with 40% less energy** into the eye. The platform also features a first-of-its-kind phaco handpiece that estimates temperature at the incision site.[1,2,3] The UNITY VCS/CS system has also received international recognition for innovation in surgical technology. Earlier this year, Alcon was named the Overall Winner in the 2026 BIG Innovation Awards for UNITY VCS, recognized for transforming ophthalmic surgical workflows through innovation and measurable impact. More recently, UNITY VCS received a Silver Edison Award in the Surgical Robotics & Precision Therapy category, recognizing the platform's advancements in surgical precision and workflow integration. UNITY VCS and UNITY CS are among the newest innovations from the Alcon Vision Suite, a portfolio of products designed to help eye care professionals increase clinic and operating room efficiency. "Together, these innovations reflect Alcon's continued focus on advancing the future of ophthalmic care in Canada," Newson added. "This is just the beginning as we continue to build on the UNITY platform to deliver a new standard of connected surgical innovation for Canadian ophthalmology." With a heritage spanning more than 75 years, Alcon claims to offer the broadest portfolio of products to enhance sight. Each year, Its Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. The company's more than 25,000 associates enhance the quality of life through products, partnerships with eye care professionals, and programs that advance access to quality eye care. UNITY Vitreoretinal Cataract System (VCS) is Alcon's most advanced surgical platform designed to support both vitreoretinal and cataract procedures within one integrated platform, and UNITY Cataract System (CS) is a standalone cataract system. The UNITY platform delivers surgical care for patients with vision-threatening eye conditions by helping surgeons operate with greater consistency, stability, and efficiencies over Alcon's current systems, the CONSTELLATION Vision System for vitreoretinal and combined procedures, [,] [,] ‡ and CENTURION Vision System with ACTIVE SENTRY for cataract surgery.***[,4] UNITY VCS and UNITY CS leverage a novel phacoemulsification modality to deliver up to two times faster nucleus removal^ with 40% less energy* into the eye,[2] and a first-of-its-kind phaco handpiece that estimates temperature at the incision site.[3] ^ 2x faster nucleus removal than OZIL Torsional phaco * Per reduction in cumulative dissipated energy (CDE) ** Based on N=10 HPs, Artificial cataract lens IOP 55 mmHg vacuum of 450 mmHg *** Based on bench data. Reduction in surge is correlated to less change in anterior chamber depth. For posterior segment surgeries/posterior cassette pack. (P<0.001). ‡ ~1 minute faster. References [1] Alcon Data on File, 2024 - REF-24379. [2] Alcon Data on File, 2024 - REF-24644. [3] Unity VCS User Manual 2024 - REF-24980. [4] lcon Data on File, 2024 - REF-25374.

Alcon has priced a public offering of €500 million aggregate principal amount of 3.875% senior notes due 2033. The notes will be issued by Alcon Finance Corporation, a wholly owned subsidiary of Alcon, and will be guaranteed by Alcon Inc. The notes will be listed on the Luxembourg Stock Exchange and admitted to trading on the Euro MTF. The offering is expected to close on 2 September 2026, subject to customary closing conditions. Alcon intends to use the proceeds for general corporate purposes, which may include refinancing existing debts. The company is a global leader in eye care, serving over 260 million people across more than 140 countries with its surgical and vision care products.

Alcon's Q2 2026 growth shows UNITY momentum, but cataract softness and Implantables competition still matter. What the latest reported quarter says about the current operating story and the main business drivers. Alcon Inc. (NYSE: ALC) reported second-quarter 2026 net sales of $2.782 billion, up 8% year over year on a reported basis and up 7% on a constant-currency basis, while core diluted EPS rose to $0.84 from $0.76 in the prior-year quarter (Alcon Q2 2026 press release). The headline is not a simple demand boom. The quarter showed solid commercial execution across several newer products, but it also showed that the company still needs faster recovery in cataract-related demand and better stability in Implantables. Discover more financial news Stock performance tracking Stock research tools The clearest operating split was inside Surgical. Total Surgical sales were $1.570 billion, up 8% reported and 7% constant currency. Within that, Implantables contributed $466 million, up 2% reported and just 1% constant currency. Alcon said that growth in intraocular lenses was driven by PanOptix Pro but also said the category reflected competitive pressures and lower sales in surgical glaucoma. Consumables were stronger at $825 million, up 6% reported and 5% constant currency, helped by procedural growth and price increases, though management still flagged continued softness in the cataract market. Equipment and other was the standout at $279 million, up 26% reported and 25% constant currency, led by recent equipment launches including the UNITY platform (Alcon Q2 2026 press release). Vision Care also contributed to the better top line. Segment sales were $1.212 billion, up 8% reported and 7% constant currency. Contact lenses generated $726 million, up 5%, with growth from product innovation and pricing partly offset by declines in legacy products. Ocular health delivered $486 million, up 13% reported and 12% constant currency, led by dry-eye products including Tryptyr and Systane. That matters because it shows Alcon is not relying on one franchise to support growth. Even so, the Surgical mix still carries disproportionate weight for investor sentiment because Implantables has historically been one of the more strategic categories in the story (Alcon Q2 2026 press release). What the latest reported revenue mix, margins, balance-sheet context, and management commentary imply for investors now. The revenue mix shows why the quarter looked better at the surface than it did underneath. In Surgical, Consumables made up the largest share of revenue at $825 million, or a little over half of segment sales. Implantables accounted for $466 million, and Equipment/other accounted for $279 million. That mix is important because the fastest growth came from Equipment/other, not from Implantables. Investors can read that two ways: as proof that product launches are working, and as evidence that the older cataract and implant base is not yet giving the company the same level of support. Stocks & Bonds Discover more Market sector analysis Market analysis reports Financial data feed Profitability tells a similar two-layer story. Reported operating margin fell to 0.4% in Q2 2026 from 9.6% a year earlier, while reported diluted EPS fell to $0.00 from $0.35. The main reason was a pre-tax, non-cash net charge of $402 million tied to Alcon's decision to discontinue the PowerVision intraocular lens programs after the latest clinical data did not produce acceptable patient outcomes. On the core basis that management emphasizes for operating performance, however, operating margin improved to 20.6% from 19.1%, and core operating income rose to $574 million from $491 million. Core gross margin also improved to 64.7% from 62.2%. In other words, the reported numbers were hit by a major one-time program decision, but the underlying commercial business still expanded margin (Alcon Q2 2026 press release; Alcon Q2 2026 interim financial report). Cash generation also stayed healthy. For the first six months of 2026, Alcon generated $928 million of net cash from operating activities and $693 million of free cash flow, both above the prior-year period. The company returned $538 million to shareholders year to date through dividends and share repurchases, including $469 million in the second quarter alone, and it still had about $1.2 billion remaining under its previously announced repurchase authorization as of June 30, 2026. That does not remove execution risk, but it does show that the company is funding investment and shareholder returns from a position of ongoing cash generation rather than from financial strain (Alcon Q2 2026 press release). Discover more Business news updates Management's commentary was also constructive but not carefree. CEO David Endicott said recent launches including UNITY, PanOptix Pro, and Tryptyr are driving growth and strengthening Alcon's innovation engine. At the same time, the company maintained its 2026 net sales growth outlook at 5% to 7% constant currency rather than raising it, while increasing its outlook for core operating margin expansion to 90 to 190 basis points from 70 to 170 basis points and raising core diluted EPS growth to 12% to 15% from 10% to 13%. That combination implies management sees a better earnings path through mix, efficiencies, and launch execution more than through a step-change in end-market demand (Alcon Q2 2026 press release). What investors should watch next. The next question is whether Equipment momentum can stay strong enough to offset a slower Implantables backdrop. UNITY clearly helped the quarter, but investors will want to see whether Alcon can keep that platform adoption moving after the initial launch wave. If Equipment/other growth slows before Implantables improves, the Surgical narrative could look less balanced. Implantables is the second key watch item. The Q2 result did not show a collapse, but 1% constant-currency growth is a thin cushion for a category facing competitive pressure. Investors should look for evidence that PanOptix Pro can keep premium lens demand healthy enough to counter lower glaucoma sales and broader cataract softness. If that does not happen, the category could stay a drag on the mix even while the rest of the portfolio grows. The third watch item is how much of the raised earnings outlook comes through as durable operating improvement. Alcon now expects 2026 core EPS growth of 12% to 15% and still expects aggregated markets to grow about 3% to 4%. It also expects a net tariff impact of about $40 million to $90 million for the year, after mitigating actions and refunds. That means investors should watch margin delivery at least as closely as revenue growth. The quarter suggests Alcon can protect profitability through pricing, manufacturing efficiency, and launch mix, but the durability of that formula matters more than one quarter's beat. Key signals for investors. * Q2 2026 revenue growth was solid, but the strongest Surgical contribution came from Equipment/other, not Implantables. * Implantables grew only 1% constant currency, and management explicitly cited competitive pressures and lower glaucoma sales. * The $402 million PowerVision charge crushed reported profitability, but core margin and core EPS still improved year over year. * First-half operating cash flow of $928 million and free cash flow of $693 million supported both investment and shareholder returns. * Raised 2026 core EPS guidance suggests management sees more earnings leverage ahead, but the sales outlook staying at 5% to 7% constant currency shows demand questions are not fully resolved. Sources. https://s1.q4cdn.com/963204942/files/doc_earnings/2026/q2/earnings-result/Q2-2026-Press-Release.pdf https://s1.q4cdn.com/963204942/files/doc_earnings/2026/q2/filing/Q2-2026-Interim-Financial-Report.pdf